MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.13
+0.11
+1.83%
After Hours: 6.25 +0.12 +1.96% 18:41 05/11 EDT
OPEN
5.90
PREV CLOSE
6.02
HIGH
6.30
LOW
5.74
VOLUME
157.32K
TURNOVER
--
52 WEEK HIGH
19.10
52 WEEK LOW
2.460
MARKET CAP
80.78M
P/E (TTM)
-7.2786
1D
5D
1M
3M
1Y
5Y
This May be a Safer Way for Millions to Treat Arthritic Pain
May 07, 2021 (Baystreet.ca via COMTEX) -- Millions of people all over the world deal with arthritic pain. In fact, just in the U.S., the Centers for Disease...
Baystreet.ca · 4d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Benzinga · 05/04 16:41
Edesa Biotech to Host Key Opinion Leader Webinar on EB05 for the Treatment of Acute Respiratory Distress Syndrome
Virtual event scheduled for Thursday, April 29 at 1 pm Eastern TimeTORONTO, ON / ACCESSWIRE / April 22, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced toda...
ACCESSWIRE · 04/22 12:00
Insider Buys Edesa Biotech Inc.'s Stock
Shares of Edesa Biotech Inc (NASDAQ:EDSA) fell by 4.45% from the previous closing price. President *Brooks Michael J filed a Form 4 with the SEC on Thursday, March 25. The insider bought 4,500 shares at an average price of $5.08. After the transaction, the...
Benzinga · 03/26 15:14
Who Has Been Buying Edesa Biotech, Inc. (NASDAQ:EDSA) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Simply Wall St. · 03/26 07:10
Edesa Biotech Expands Rights to Anti-Inflammatory Technology
TORONTO, ON / ACCESSWIRE / March 22, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that it has entered into a definitive license agreement under whi...
ACCESSWIRE · 03/22 12:45
Edesa Biotech stock surges after expanding rights to anti-inflammatory technology
Edesa Biotech (EDSA) shares up more than 16% premarket after the company announced that it has entered into a definitive license agreement to acquire additional global rights to a non-steroidal anti-inflammatory technology
Seekingalpha · 03/22 12:24
BCRX, NGA, SESN and KSU among premarket gainers
Support.com (SPRT +271% as Greenidge Generation Holdings to go public via merger with the company.Seneca Biopharma (SNCA) +30%.Cemtrex (CETX) +21%.Marker Therapeutics (MRKR) +19%.Acer Therapeutics (ACER) +19%.Kansas City Southern (KSU +17% as Canadian Paci...
Seekingalpha · 03/22 12:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EDSA. Analyze the recent business situations of Edesa Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EDSA stock price target is 17.00 with a high estimate of 18.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 17
Institutional Holdings: 231.66K
% Owned: 1.76%
Shares Outstanding: 13.18M
TypeInstitutionsShares
Increased
3
15.62K
New
2
96.59K
Decreased
3
46.71K
Sold Out
2
3.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Non-Executive Chairman/Independent Director
Sean MacDonald
President
Michael Brooks
Chief Executive Officer/Secretary/Director
Pardeep Nijhawan
Chief Financial Officer
Kathi Niffenegger
Director
Frank Oakes
Independent Director
Lorin Johnson
Independent Director
Paul Pay
Independent Director
Carlo Sistilli
Independent Director
Peter van der Velden
No Data
About EDSA
Edesa Biotech Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical-stage drugs for dermatological and gastrointestinal indications. Its lead product candidate, EB01, is an sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD). Its pipeline also includes EB02 and EB04. EB02, an sPLA2 inhibitor, is being developed as a treatment for patients with hemorrhoids disease (HD). EB04 is being developed for anal fissures. It is also focused on developing biologic drug candidates for therapeutic, prophylactic and diagnostic applications.

Webull offers kinds of Edesa Biotech Inc stock information, including NASDAQ:EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.